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PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or
reverse steroid-induced IOP elevation in an ovine model.
METHODS. Three animal groups were subjected to bilateral steroid-induced IOP elevation using
thrice daily topical ocular prednisolone administration. In the first group (N ¼ 8), one eye
each of two sheep was injected intravitreally with 100 lg, 200 lg, 500 lg, or 1 mg human
recombinant tPA, while contralateral eyes received vehicle. In the second group (N ¼ 2), one
eye was injected intravitreally with tPA (100 lg), while contralateral eyes received vehicle
containing L-arginine. In the third group (N ¼ 4), each animal received intravitreal tPA in one
eye concurrently with initiation of bilateral steroid administration. IOP was monitored for the
duration of the experiment. Tissues from eyes of the third group were used to determine
relative gene expression.
RESULTS. In the first and second groups, IOP decreased by 9.7 (62.8) and 9.7 (61.6) mm Hg,
respectively, 24 hours after tPA administration. In the third group, tPA-treated eyes did not
develop IOP elevation with DIOP of 11.8 (61.3) mm Hg 8 days later. In all tPA-treated eyes,
IOP remained low until the end of the study. mRNA levels in the trabecular meshwork were
decreased for plasminogen activator tissue (PLAT), increased for matrix-metalloproteinase 1
(MMP-1), and stable for plasminogen activator inhibitor 1 (PAI-1), MMP-2, MMP-9, and MMP-
13 in tPA-treated eyes compared with contralateral controls. PAI-1 mRNA levels in ciliary
processes also remained similar.
CONCLUSIONS. Recombinant human tPA is effective in both preventing and reversing steroid-
induced IOP elevation in sheep. Tissue plasminogen activator may be useful as a therapeutic
agent in steroid-induced glaucoma.
Keywords: intraocular pressure, tissue plasminogen activator, trabecular meshwork,
extracellular matrix, matrix metalloproteinase
Tissue plasminogen activator (tPA) is a serine protease thatcatalyzes the conversion of the zymogen, plasminogen, to
plasmin, the major enzyme responsible for blood-clot break-
down via the proteolytic degradation of fibrin.1 This cascade
can also lead to the activation of other proenzymes, including
members of the matrix-metalloproteinase (MMP) family of
enzymes, to their active forms.2,3 The MMPs directly degrade
extracellular matrix (ECM) components, and these enzymes
play a key role in the turnover and maintenance of the ECM of
the trabecular meshwork (TM), a process affecting outflow
facility.4,5 Because tPA is expressed, and secreted, by various
organ systems including the TM6,7 and is found in the aqueous
humor,8 tPA could have an important role in controlling or
regulating ECM composition in the TM. Consistent with this
possibility, glucocorticosteroid drugs, such as dexamethasone,
which have been shown to increase the accumulation of ECM
components in the TM and decrease outflow facility,9,10 also
elicit reductions in tPA activity in TM organ and cell cultures,11
suggesting a linkage between these phenomena.
Glucocorticosteroids are therapeutically versatile and com-
monly administered as anti-inflammatory, immunosuppressive,
and anti-angiogenic agents.12–15 However, glucocorticosteroids
also elicit adverse ocular effects such as cataracts and increased
IOP.16 Individuals susceptible to the latter side effect may
require treatment for glaucoma. The phenomenon of gluco-
corticosteroid-induced ocular hypertension has been recog-
nized for decades,17 and a number of predisposing risk factors
have been identified among patients receiving various cortico-
steroid treatments.18,19 In general, it is recognized that the
mechanisms by which glucocorticosteroids induce the IOP
elevation involve a reduced trabecular aqueous humor outflow
associated with morphologic and biochemical changes in the
TM.18,19 As such, studies on the cellular processes eliciting
corticosteroid-induced ocular hypertension may shed light on
the cause of POAG.
In past work, we demonstrated the effectiveness of using
Corriedale sheep (Ovis aries) as an animal model for
glucocorticosteroid-induced ocular hypertension.20 The IOP
of these animals increased approximately 2-fold within 1 to 2
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weeks of topically applying 0.5% prednisolone acetate three
times daily. This IOP elevation occurred with a 100% incidence
in the corticosteroid-treated eyes. In the current work, we
attempted to determine the effect of intravitreally administered
human recombinant tPA on steroid-induced IOP elevation in
sheep. This study is the first to examine the effects of
exogenously administered tPA on IOP in an animal model in
vivo.
MATERIALS AND METHODS
Animals—Care, Husbandry, and General
Experimental Procedure
All animal experiments were performed in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. A total of 14 healthy (female) sheep
(Corriedale breed) between 12 and 24 months of age, weighing
35 to 40 kg, were selected from a local ranch in Corrientes,
Argentina, for this study. The eyes and general health of the
animals were considered normal by an ophthalmologist and a
veterinarian, respectively. Sheep were tagged on their ear lobes
for individual identification and herded from pasture whenever
it was necessary to (1) topically instill prednisolone, (2) inject
either tPA or vehicle intravitreally, or (3) measure IOP by
applanation tonometry. For each of these procedures, the
sheep were guided into a funnel corral ending in a loose-fitting
yoke.20 This arrangement allowed movement and holding of
the head by one person, while another either instilled the
prednisolone, completed the intraocular injections, or mea-
sured IOP. Between all procedures, the animals were free to
pasture.
Prednisolone Instillation Protocol
All sheep eyes received two drops of 0.5% prednisolone
acetate (Ultracortenol; Novartis Ophthalmics, Hettlingen,
Switzerland), three times daily (at 7 AM, 2 PM, and 7 PM) for
the duration of each experiment. Such treatment induces a
persistent ocular hypertension in sheep provided the instilla-
tion protocol is uninterrupted.20
Intravitreal Injection of tPA
Lyophilized tPA (Actilyse, 50 mg; Boehringer, Ingelheim,
Germany) was dissolved in 0.1 mL balanced saline solution
(BSS), which was then injected into the central vitreous under
topical anesthesia (induced with two drops of topical
Anestalcon [proparacaine, 0.5%; Alcon, Buenos Aires, Argenti-
na]). The amounts of tPA introduced into the eye within the
0.1 mL quantity of vehicle ranged from 0.1 mg to 1 mg. For
these injections, a disposable insulin syringe with a 12.7-mm,
30-gauge needle was used to penetrate the globe to the full
length of the needle at a point approximately 4 mm posterior
to the limbus. The angle of penetration was such that the tip of
the needle was centrally located within the vitreous humor.
Care was taken to avoid puncturing the lens upon injection.
In one group of animals (N¼ 8), the right eye of each sheep
received the tPA-containing solution (0.1 mg, 0.2 mg, 0.5 mg, 1
mg, respectively; two animals per dose), whereas the left eye
solely received vehicle (BSS) intravitreally, after 10 days of daily
prednisolone instillations three times a day in both eyes.
Prednisolone treatment continued after tPA administration for
the duration of the experiment.
A second group of animals (N ¼ 2) was treated as above
with 0.1 mg tPA, but instead of BSS, the contralateral eye
received 4.23 mg arginine in BSS. This amount is equivalent to
the amount of arginine contained in 0.1-mg commercial tPA
preparation. Prednisolone treatment initiated 7 days prior to
tPA administration was bilateral as above and continued for the
duration of the experiment.
A third group of animals (N¼ 4) received 0.1 mg tPA in one
eye, while the contralateral eye received 4.23 mg arginine in
BSS. Prednisolone-acetate treatment was then initiated on the
same day and continued for the duration of the experiment.
Measurement of IOP of Conscious Sheep With the
Handheld Perkins Applanation Tonometer
IOP was measured with a Perkins tonometer (Haag Streit USA,
Mason, OH). Before the IOP measurement, two drops topical
0.5% proparacaine (Alcon) followed by two drops 0.25%
fluorescein were instilled in eyes. Two sets of measurements
were taken on each eye and averaged, alternating first one eye
and then the other. All IOP measurements were taken between
2 PM and 4 PM every 2 or 3 days. Perkins tonometry readings
were converted to mm Hg as described in detail previously.20
The IOP in both eyes of the sheep used in this study was
measured prior to any treatment to establish baseline values.
Tissue Collection and Isolation of RNA
After animals were euthanized, eyes from animals in the third
group were immediately enucleated. Eyes were then opened
anterior to the equator using a razor blade. The lens was
removed from the anterior part, and the tissue was immersed
in RNA stabilizing agent (RNAlater; Ambion, Carlsbad, CA) and
placed at 208C for transportation to the United States. Upon
arrival in the United States, TM and ciliary processes (CP) were
dissected on ice in the presence of RNA stabilizing agent as
described previously.21 Dissected tissue was homogenized, and
total RNA was extracted using TRIzol reagent (Gibco, Carlsbad,
CA). Briefly, the tissue was homogenized in TRIzol, and
chloroform was added to separate proteins from RNA. After
centrifugation, the RNA-containing supernatant was aspirated.
The RNA was precipitated with isopropanol, washed with 75%
ethanol, treated with DNase, and column purified using a
commercial kit (RNAeasy Mini Kit; Qiagen, Valencia, CA) in
accordance with the manufacturer’s instructions. RNA con-
centrations were determined with a spectrophotometer
(Nanodrop; Thermo Scientific, Wilmington, DE) and the
260:280-nm absorbance ratio was calculated to determine
RNA purity.
Quantitative Real-Time PCR (qRT-PCR)
The RNA samples were reverse transcribed with random
hexamers to cDNA using a reverse transcription kit (Quanti-
tect; Qiagen) in accordance with the manufacturer’s instruc-
tions. Quantitative RT-PCR was performed using a commercial
kit (SYBR Green RT-PCR Reagents Kit; Applied Biosystems,
Carlsbad, CA) in an ABI PRISM 7900HT sequence detector
(Applied Biosystems). The sheep endogenous mRNA expres-
sion of matrix metalloproteinase-1 (MMP-1), matrix metal-
loproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9),
matrix metalloproteinase-13 (MMP-13), and plasminogen
activator tissue (PLAT) in the TM were investigated. Plasmin-
ogen activator inhibitor 1 (PAI-1) mRNA expression was
measured in both TM and CP tissues. The primer sequences
used are listed in the Table. Relative quantification of gene
expression was performed using the standard curve method.
Mean threshold cycle (Ct) of the samples was compared
among the groups by using the Ct of 18S as an internal control.
The DCt was calculated as the difference in Ct values derived
from the target gene and the 18S gene. The DDCt was
Reduction of Steroid-Induced IOP in Sheep by tPA IOVS j December 2013 j Vol. 54 j No. 13 j 7904
Downloaded From: http://arvojournals.org/ on 04/27/2015 Terms of Use: 
calculated as DCt of the normalized assayed genes in the
treated samples minus DCt of normalized assayed genes in the
na¨ıve control samples. Relative expression was calculated by
the 2DDCt formula.
Data Analysis
Differences in IOP between contralateral eyes were subjected
to ANOVA with post hoc Tukey-Kramer testing. IOPs at specific
individual time points were compared using t-test. Gene
expression fold changes were compared with one using one-
sample t-test; a¼ 0.05 was chosen as the level of significance.
RESULTS
Baseline IOPs for all sheep prior to any experimental
intervention was between 9 and 12 mm Hg. Treatment with
prednisolone acetate for 10 days increased mean (6SD) IOP to
24.2 (61.6) mm Hg for all animals in group 1. This pressure
level was statistically significantly different from baseline mean
IOP, which was 10.2 (61.1) mm Hg (P < 0.00001, t-test) (Fig.
1).
Treatment with tPA decreased IOP within 24 hours for all
doses tested in the first group of animals to a mean (6SD) of
14.5 (61.1) mm Hg, which was significantly lower than of the
contralateral control eye, which exhibited an IOP of 24.2
(62.4) mm Hg (P < 0.000013, paired t-test). The effect was
evident for all tPA doses, independent of the dose (P > 0.27,
ANOVA). IOP remained different between contralateral control
eyes and tPA-treated eyes for at least 9 days, after which IOPs
became similar (P < 0.00001, ANOVA, Tukey-Kramer post hoc
test) (Fig. 1). Transient injection and corneal clouding was
observed in five eyes but was unrelated to the dose injected
(two eyes in the 1-mg dose, and one eye each in the other
doses). The corneal clouding and injection was initially noted 3
days after tPA injection and resolved in all eyes within a
maximum of 5 days (before IOP became similar to that of the
contralateral eye).
Similarly, in the animals treated with 100 lg tPA in one eye,
while the contralateral eye received arginine, IOP decreased
from a mean (6SD) of 21.3 (61.5) mm Hg to a mean (6SD) of
13.7 (60.0) mm Hg (P < 0.003, ANOVA, Tukey-Kramer post
hoc test) within 24 hours in the tPA-treated eye. No significant
change in IOP occurred in the arginine-treated eye with IOP
remaining elevated to a mean (6SD) of 23.4 (61.6) mm Hg
(Fig. 2). No eyes (neither tPA injected nor arginine injected)
showed any evidence of corneal clouding for the duration of
the experiment.
In the third group of animals that received tPA concurrently
with initiation of steroid treatment, IOP remained similar in the
tPA- and arginine-treated eyes until day 5, with the mean IOP of
the tPA-treated and control eyes exhibiting values of 15.4
(61.1) and 15.9 (60.0) mm Hg (P > 0.06, paired t-test),
respectively. Eight days after tPA injection, the IOP of the
treated eyes declined to 11.6 (60.0) mm Hg, while that of the
control eyes increased to 23.4 (61.3) mm Hg. The IOP
difference between tPA-treated and arginine-treated eyes was
significantly different over time (P < 0.00001, ANOVA) with
IOP difference on days 5 and 8 being significantly different
from that at earlier time points (Tukey-Kramer post hoc test).
This IOP difference remained for the duration of the
experiment (Fig. 3). No eyes (neither tPA injected nor arginine
injected) showed any evidence of corneal clouding for the
duration of the experiment.
Expression of PLAT gene in the TM of tPA-treated eyes was
significantly decreased (P < 0.01, t-test) compared with that of
the contralateral control arginine-treated eyes in the four
animals where treatment with steroids was initiated concur-
rently with tPA administration. PLAT mRNA expression
decreased by approximately 50%. In contrast, expression of
PAI-1 was not significantly different among contralateral eyes
in this group of animals in either the TM or the CPs (P > 0.05,
t-test) (Fig. 4).
Expression of MMP-1 in the TM of tPA-treated eyes was
significantly upregulated (P < 0.05, t-test) compared with that
of the contralateral control arginine-treated eyes. MMP-1
mRNA expression increased by approximately 80%. The
expression of MMP-2, MMP-9, and MMP-13 was not signifi-
cantly different between the groups (P > 0.05) (Fig. 4).
DISCUSSION
The fibrinolytic system is a complex system of proteins that
controls clotting of blood and subsequent dissolution of the
resulting thrombus. Tissue plasminogen activator and uroki-
nase plasminogen activator (uPA) are two separate molecules
that activate plasminogen, which then becomes plasmin that
degrades fibrin.1 However, tPA has also activity at the cellular
FIGURE 1. IOP (mean 6 SD) in intravitreally tPA-treated and
contralateral control eyes of sheep (N ¼ 8). All eyes were also treated
with prednisolone acetate starting 10 days prior to tPA administration
and continuing for the duration of the experiment. Among experi-
mental group two eyes each received tPA doses of 0.1, 0.2, 0.5, and 1
mg. IOP decreased within 24 hours in tPA-treated eyes and remained
lower than that of the contralateral eyes for at least 9 days. **P <
0.0001, t-test; ***P < 0.00001 ANOVA, post hoc testing.
TABLE. Primer Sequences of Genes Analyzed by qRT-PCR
Gene Primer Sequence, 50–30
Size,
bp
MMP-1 Forward AAGATGTGGAGACGGTGCAG 144
Reverse CAGTCACTCTCAGCCCGAAG
MMP-2 Forward ACATACAGGATCATTGGCTACACA 214
Reverse CGAAGGCATGAGCCAGGAG
MMP-9 Forward CCAGGAGAACGACGAACCAG 248
Reverse AGTTCGCCCTCAAAGGTCTG
MMP-13 Forward GCCAGAACTTCCCAACCGTA 181
Reverse GTGAAGGGCTGCACTGATCT
PLAT Forward CAGTGCCCAGAAGGGTTCAT 249
Reverse GTAGCACCAGGGCTTTGAGT
PAI-1 Forward CTCCAAGGACCGCAACGT 199
Reverse GCTGATCTCATCCTTGTTCCA
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level for controlling ECM remodeling and has been implicated
in cell proliferation and migration.22 Tissue plasminogen
activation is controlled by endogenous inhibitors (plasminogen
activator inhibitors 1 and 2).2 PAI-1 has been reported to be
elevated in glaucoma in the past23 and has been shown to be
synthesized by both the ciliary epithelium24 and TM cells in
response to TGFb,25 a known factor that induces reduction in
outflow facility.25,26 Tissue plasminogen activator has also been
reported to be downregulated in organ cultures after treatment
with steroids.10,11
A number of publications describe the use of human
recombinant tPA either intracamerally for the acute manage-
ment of excessive fibrin in the anterior segment of the eye27–30
or intravitreally for the dissolution of subretinal hemorrhag-
es.31–33 Although IOP reductions are often mentioned, they
have been attributed to the dissolution of the fibrin clot in the
anterior chamber. However, to date, no attempt has been made
to modulate the fibrinolytic system for therapeutic purposes in
steroid-induced or open-angle glaucoma.
The present experiments were designed to determine
whether intravitreal administration of tPA in a sheep-animal
model of glucocorticosteroid-induced ocular hypertension
could both (1) reduce the elevation in IOP after its
establishment by pretreatment with the corticosteroid pred-
nisolone and (2) prevent such IOP elevation. In the present
study, prednisolone was administered by thrice-daily topical
instillations, as used previously.34 With this agent, the IOP of
sheep increases after approximately 7 days of treatment and
remains elevated for as long as the instillation regimen is
maintained (Danias J, Candia O, Gerometta R, unpublished
observations, 2010). We administered human recombinant tPA
by intravitreal injection. Intravitreal administration creates a
depot for proteins, which are slowly eliminated in large part
through the anterior segment. Although the kinetics of
plasminogen in the vitreous cavity are unknown, administra-
tion of anti-VEGF antibodies results in high concentrations in
the aqueous within 24 hours, which decline in a mono-
exponential manner.35 Half-life for the vitreal depot has been
calculated for anti-VEGF antibodies to be approximately 9 days
in nonvitrectomized eyes.36 Based on the results of the current
study, it is difficult to speculate what the half-life of intra-
vitreally administered tPA may be. However, given the similar
pattern of IOP change in the animals that received various
doses of tPA and the effects on gene expression, it can be
hypothesized that either tPA affects ECM molecules that have a
very slow turnover or that the amount of tPA injected affects
the rate at which it is eliminated. Testing of these hypotheses
requires additional work.
The first group of animals reported in this study represent-
ed an attempt to perform a dose-response curve utilizing
relatively high doses of tPA (range, 0.1–1 mg). We were
surprised to find out that even the lowest dose (100 lg) caused
significant and sustained (over 9 days) pressure reduction in
this animal model. Because all animals (irrespective of dose)
exhibited the same effect on IOP, we analyzed them as a group.
Some eyes developed injection and transient corneal clouding
that resolved within a maximum of 5 days. However, this was
not dose dependent (observed in some eyes only at all dose
levels). It is thus unclear whether effects on the cornea are the
result of tPA itself, protein aggregates that may have formed
during the reconstruction and injection process, or arginine
that is used to ensure the commercial tPA stability. In addition,
no corneal or conjunctival effects were seen in the second and
third group of animals.
Tissue plasminogen activator has been used clinically in
acute situations by intracameral injection usually at a dosage of
10 to 25 lg.28,37 For intravitreal use, it has been used to
dissolve submacular hemorrhages at a dosage of 30 to 100 lg.32
Retinal toxicity has been reported with doses above 75 to 100
lg but has been attributed to the presence of arginine in the
commercial preparations.38–40 Toxicity usually develops early
and manifests as diffuse pigmentary alterations. We did not
observe any pigmentary changes during the course of these
experiments (even at maximal dosing), but we did not test the
animals electrophysiologically and have not histologically
examined the retina as our focus was the effect on IOP.
However, to ensure that arginine present in the commercial
tPA preparation (which can be a nitric oxide donor)41 is not
responsible for the effect on IOP observed, we treated an
FIGURE 3. IOP (mean 6 SD) in intravitreally tPA-treated and
contralateral control eyes of sheep (N ¼ 4). All eyes were also treated
with prednisolone acetate starting immediately after tPA administration
and continuing for the duration of the experiment. Tissue plasminogen
activator–treated eyes received 100 lg of tPA each, while contralateral
eyes received the equivalent amount of arginine (4.23 mg). IOP in tPA-
injected eyes remained low, while it increased in arginine-treated eyes
7 days after injection. ***P < 0.00001, ANOVA, post hoc testing.
FIGURE 2. IOP (mean 6 SD) in intravitreally tPA-treated and
contralateral control eyes of sheep (N ¼ 2). All eyes were also treated
with prednisolone acetate starting 7 days prior to tPA administration
and continuing for the duration of the experiment. Tissue plasminogen
activator–treated eyes received 100 lg of tPA each, while contralateral
eyes received the equivalent amount of arginine (4.23 mg). IOP
decreased within 24 hours in tPA-treated eyes and remained lower than
that of the contralateral eyes for at least 7 days. *P < 0.003, ANOVA,
post hoc testing.
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additional two animals with the lowest dose of tPA used in the
initial group (100 lg), while their contralateral eye received
the equivalent amount of arginine dissolved in BSS. As for
animals in the first group, tPA caused a significant and
sustained (at least 8 days) drop in IOP, while contralateral
eyes receiving arginine did not show any appreciable effect.
This finding confirms that tPA administered intravitreally has a
specific effect on reducing IOP that is elevated by steroid
treatment in this animal model and is in agreement with
findings in a mouse model of steroid-induced facility changes
(currently in review) that shows a specific effect of tPA on
outflow facility.
We also sought to determine whether tPA administration
can prevent steroid-induced IOP elevation. We thus adminis-
tered tPA just prior to initiation of treatment with steroids. As
mentioned above, IOP elevates in the ovine model after
approximately 1 week of treatment with steroids. Tissue
plasminogen activator (100 lg) administered intravitreally was
effective in preventing steroid-induced IOP elevation, and this
effect lasted for at least 5 days.
Although tPA as a serine protease has a direct effect on a
number of other enzymes, such effects are usually short
lived.42,43 Tissue plasminogen activator has, however, also
been shown to affect gene expression through various
pathways.44,45 Since the effects of tPA on steroid-induced
IOP elevation appear to be prolonged, we investigated
whether tPA (either directly or indirectly) causes changes in
the expression of a number of relevant genes in the TM and CP.
The fibrinolytic system is tightly regulated.1,46 Thus, we first
investigated whether PAI-1 expression is affected. PAI-1 is
expressed both in the CP and locally in the TM24,25 and has
been proposed to affect outflow facility.26,47 Despite the fact
that administration of tPA was intravitreal, we did not detect
any changes in the mRNA levels of PAI-1, suggesting that the
observed effect on IOP was directly the result of tPA (increased
PAI-1 expression would have counteracted tPA-mediated IOP
lowering, while decreased PAI-1 expression would have
augmented tPA action and may have mediated the tPA effect).
Our results suggest that tPA administration does not act
through downregulating PAI-1 expression. Of interest, endog-
enous PLAT gene was downregulated in the sheep TM,
suggesting the presence of a feedback loop that regulates
local tPA production.
Tissue plasminogen activator is known to affect levels of
MMPs in a variety of systems including the TM.10,45,48,49
Although tPA mediates plasminogen and proMMPs’ activation
by proteolytic cleavage, it also has effects on gene expression
of MMPs.44,50–52 MMPs are a family of zinc- and calcium-
dependent enzymes able to degrade ECM components. MMP-1
and MMP-13 are interstitial collagenases that degrade collagen
type I, collagen type III, and collagen type IV.53,54 MMP-2
(gelatinase A) and MMP-9 (gelatinase B) are able to degrade
major components of ECM such as collagens type IV, V, VII, and
X, laminins, and fibronectin. MMPs play a key role in the
turnover and maintenance of the trabecular meshwork’s ECM
and have been shown to be involved in trabecular outflow.4,5
Because MMPs are involved in ECM turnover, and tPA can
affect the levels of MMPs, we investigated whether any of the
relevant MMPs were upregulated in the TM after tPA
administration. Of interest, only MMP-1 mRNA was upregu-
lated, while mRNA levels for MMP-2, MMP-9, and MMP-13 did
not change. MMP-1 upregulation has been shown by our group
to have a similar effect to tPA administration on IOP in this
animal model.34 It is thus possible that tPA is acting upstream
of MMP-1 to regulate ECM degradation, which eventually leads
to IOP reduction.
It appears that some of the effects of PAI-1 on the TM are
mediated through activation of MMP- 2 and MMP-9 in the TM.25
It is thus interesting that the absence of changes in PAI-1
mRNA were accompanied by a lack of changes in the mRNA
levels of MMP-2 and MMP-9, both of which have been
implicated in IOP elevation pathophysiology.4,55
In summary, we present evidence that tPA intravitreal
administration can both decrease and prevent steroid-induced
IOP elevation and that this effect appears to be related to MMP-
1 upregulation. The work described in the current manuscript
has been performed in the highly relevant to human disease
ovine steroid-induced IOP elevation model. Although we
acknowledge that, as with work on any animal model, the
results may not necessarily reflect what happens in humans
and need to be confirmed in ex vivo studies with human tissue,
these findings may hold important therapeutic implications for
steroid-induced and potentially other open-angle glaucomas.
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